heparin(redirected from Sodium heparin)
Also found in: Dictionary, Thesaurus, Encyclopedia.
heparin/hep·a·rin/ (hep´ah-rin) a sulfated glycosaminoglycan of mixed composition, released by mast cells and by blood basophils in many tissues, especially the liver and lungs, and having potent anticoagulant properties. It also has lipotrophic properties, promoting transfer of fat from blood to the fat depots by activation of lipoprotein lipase. It is used as the calcium or sodium salt in the prophylaxis and treatment of disorders in which there is excessive or undesirable clotting and to prevent clotting during extracorporeal circulation, blood transfusion, and blood sampling.
heparinHematology A sulfated glycosaminoglycan anticoagulant that inhibits activated factors IXa, Xa, XIa, XIIa and thrombin, ↓ local anti-thrombin-III, promoting its inactivation by neutrophil elastase; interaction of heparin with endothelial cells results in displacement of platelet factor 4, which inactivates heparin Indications Thromboembolism, CAD, post acute MI, PTE Monitoring Titrate heparin so that aPTT is 1.5-2.0-fold normal Side effects Hemorrhage, thrombocytopenia, osteoporosis, skin necrosis, alopecia, hypersensitivity, hypoaldosteronism. See Low-molecular weight heparin.
heparinA complex polysaccharide organic acid found mainly in lung and liver tissue. Heparin is thought to bind to THROMBIN and antithrombin in plasma thereby assisting in their combination and interfering with the cascade of reactions that end in blood clotting (coagulation). From the Greek hepar , the liver. The drug is on the WHO official list. Heparin is widely used as an anticoagulant under brand names such as Calciparine, Canusal, Hepsal, Monoparin and Multiparin. See also LOW MOLECULAR WEIGHT HEPARIN.
heparina mucopolysaccharide molecule produced in the liver and some white blood-cells that acts as an anticoagulant, inhibiting the transformation of prothrombin to thrombin, a vital stage in BLOOD CLOTTING.
heparinendogenous, short-acting anticoagulant that prevents platelet agglutination and thrombus formation; used as a continuous infusion in the treatment of deep venous thrombosis (DVT)
low-molecular-weight heparin longer-acting heparin derivatives, e.g. Fragmin 2500 units (used as subcuticular injection 1-2 hours before orthopaedic surgery, and thence daily for 5-7 days) to minimize postoperative DVT, or as 5000 unit injections daily (as treatment of DVT)